| Predicate |
Object |
| contentType |
Journal Article |
| endingPage |
165 |
| issn |
1439-3972
1439-6637 |
| issueIdentifier |
3 |
| pageRange |
156-165 |
| publicationName |
The European journal of health economics : HEPAC : health economics in prevention and care |
| startingPage |
156 |
| bibliographicCitation |
Tavakoli M. Disease progression in amyotrophic lateral sclerosis. Identifying the cost-utility of riluzole by disease stage. Eur J Health Econ. 2002;3(3):156–65. doi: 10.1007/s10198-002-0110-0. PMID: 15609140. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fd40ff7b1611ee742b8d6fee02308ee0 |
| date |
200209 |
| identifier |
https://doi.org/10.1007/s10198-002-0110-0
https://pubmed.ncbi.nlm.nih.gov/15609140 |
| isPartOf |
https://portal.issn.org/resource/ISSN/1439-3972
https://portal.issn.org/resource/ISSN/1439-6637 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
https://scigraph.springernature.com/ |
| title |
Disease progression in amyotrophic lateral sclerosis. Identifying the cost-utility of riluzole by disease stage |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5070
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9523
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6865 |